S-1 Plus Leucovorin and Oxaliplatin in Combination with Lentinan as First-line Therapy in Patients with Metastatic Gastric Cancer

• Kenji Ina

  Department of Psychosomatic Medicine, Nagoya Memorial Hospital, Japan

• Ryuichi Furuta

  Department of Medical Oncology, Nagoya Memorial Hospital, Japan

• Megumi Kabeya

  Department of Hospital Pharmacy, Nagoya Memorial Hospital, Japan

• Takashi Yoshida

  Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

• Takae Kataoka

  Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

• Satoshi Kayukawa

  Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

Background: Metastatic gastric cancer has a poor prognosis, despite recent therapeutic improvements. The phase 3 SOLAR study confirmed better efficacy of S-1, oxaliplatin, and leucovorin (SOL) than S-1 plus cisplatin in advanced gastric cancer. Lentinan, (1, 3)-glucan purified from Shiitake mushrooms, has been reported to improve the overall survival of cancer patients receiving chemotherapy. We conducted a preliminary study of SOL combined with lentinan during these 4 years.

Methods: The clinical study was approved by the ethics committee of Nagoya Memorial Hospital in 2016. After explaining the protocol of this study, patients with recurrent or unresectable gastric cancer were enrolled, if they had the intention to participate. Medical records were retrospectively reviewed to determine the objective response rate (ORR), disease control rate, overall survival, and adverse effects.

Results: Twelve patients (age: 59-81 years; sex: 9 men, 3 women) with metastatic gastric cancer (liver: 3, lung: 2, peritoneal: 12, ascites: 9) were treated with SOL in combination with lentinan as the first-line regimen. The cycles ranged from 4 to 15. The ORR and disease control rates were 58.3% (complete response [CR], 1; partial response, 6) and 91.7%, respectively. One patient with CR survived for > 23 months after the initiation of chemotherapy. Concerning adverse events, peripheral neuropathy was the most common event observed in all patients. However, there were no severe side effects, such as febrile neutropenia and diarrhea.

Conclusions: SOL combined with lentinan can be a promising option for the treatment of far advanced metastatic gastric cancer.

International Agency for Research on Cancer. GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide. Available online: http://globocan.iarc.fr/Default. aspx (accessed on 11 January 2021).

Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-8. https://doi.org/10.1023/A:1008243606668

Hohenberger P, Gretshel S. Gastric cancer. Lancet 2003; 362: 305-15. https://doi.org/10.1016/S0140-6736(03)13975-X

Bang Y, Van Custem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 28: 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X

Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomized, open-label, phase 3 trial. Lancet Oncol 2020; 21: 1045-56. https://doi.org/10.1016/S1470-2045(20)30315-6

Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 1969; 222: 687-8. https://doi.org/10.1038/222687a0

Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res 2009; 29: 2739-46.

Wang H, Cai Y, Zheng Y, Bai Q, Xie D, Yu J. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer Med 2017; 6: 2222-33. https://doi.org/10.1002/cam4.1156

Yoshino S, Nishikawa K, Morita S, et al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer 2016; 65: 164-71. https://doi.org/10.1016/j.ejca.2016.06.012

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity. Immunity 2013; 39: 1-10. https://doi.org/10.1016/j.immuni.2013.07.012

Tumeh PC, Harview CL, Yearley JH, et al. PD-L1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71. https://doi.org/10.1038/nature13954

Ina H, Ina K, Kabeya M, Kayukawa S, Yoshida T, Yoneda M. Lentinan, a Shiitake Mushroom β-Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells. J Analytical Oncol 2020; 9: 1-10.

Ina K, Furuta R. Image of Month: Complete response of metastatic gastric cancer to chemo-immunotherapy. Indian J Med Res 2017; 146: 141. https://doi.org/10.4103/ijmr.IJMR_132_16

Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215–21. https://doi.org/10.1016/S1470-2045(08)70035-4

Hironaka S, Sugimoto N, Yamaguchi K, et al. S-1 plus cisplatin leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomized, multicenter, open-label, phase 2 trial. Lancet Oncol 2016; 17: 99-108. https://doi.org/10.1016/S1470-2045(15)00410-6

Japnese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 ver.4. Gastric Cancer 2017; 20: 1-9. https://doi.org/10.1007/s10120-016-0622-4

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16. https://doi.org/10.1093/jnci/92.3.205

Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 2013; 48: 452-8. https://doi.org/10.1038/bmt.2012.244

Grabosch S, Bulatovic M, Zeng F, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene 2019; 38: 2380-93. https://doi.org/10.1038/s41388-018-0581-9

Fournel L, Wu Z, Stadler N, Damotte D, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small lung cancer. Cancer Letters 2019; 464: 5-14. https://doi.org/10.1016/j.canlet.2019.08.005

Aleem E. β-glucans and their applications in cancer therapy: focus on human studies. Anticancer Agents Med Chem 2013; 13: 709-19. https://doi.org/10.2174/1871520611313050005

Vetvicka V, Vetvickova J. Anti-infectious and anti-tumor activities of β–glucans. Anticancer Res 2020; 40: 3139-45. https://doi.org/10.21873/anticanres.14295

Yoshino S, Tahata T, Hazama S, et al. Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancer. Anticancer Res 2000; 20: 4707-11.

Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem 2013; 13: 681-8. https://doi.org/10.2174/1871520611313050002

Ina K, Hirade K, Kabeya M, Kataoka T, Furuta R. Long-term survivors of metastatic gastric cancer for >5 years after chemotherapy initiation. Cancer Reports and Reviews 2019; 3: 1-5. https://doi.org/10.15761/CRR.1000183

• PDF